A. Dalhoff

3.8k total citations
108 papers, 3.0k citations indexed

About

A. Dalhoff is a scholar working on Pharmacology, Molecular Medicine and Epidemiology. According to data from OpenAlex, A. Dalhoff has authored 108 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Pharmacology, 49 papers in Molecular Medicine and 33 papers in Epidemiology. Recurrent topics in A. Dalhoff's work include Antibiotics Pharmacokinetics and Efficacy (75 papers), Antibiotic Resistance in Bacteria (49 papers) and Pneumonia and Respiratory Infections (22 papers). A. Dalhoff is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (75 papers), Antibiotic Resistance in Bacteria (49 papers) and Pneumonia and Respiratory Infections (22 papers). A. Dalhoff collaborates with scholars based in Germany, United States and United Kingdom. A. Dalhoff's co-authors include Itamar Shalit, Dagmar Kubitza, Franz‐Josef Schmitz, Uwe Petersen, Rainer Endermann, Sabine Schubert, W. Weidner, U. Ullmann, Tom Bergan and R. Rohwedder and has published in prestigious journals such as Applied and Environmental Microbiology, Clinical Infectious Diseases and The American Journal of Medicine.

In The Last Decade

A. Dalhoff

103 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Dalhoff Germany 31 1.6k 1.1k 1.1k 570 488 108 3.0k
J. M. Andrews United Kingdom 33 1.8k 1.2× 1.3k 1.2× 1.5k 1.4× 552 1.0× 655 1.3× 101 3.3k
J. M. Andrews United Kingdom 35 1.8k 1.2× 1.3k 1.2× 1.4k 1.3× 684 1.2× 845 1.7× 106 4.1k
H Kropp United States 19 1.2k 0.8× 818 0.7× 1.0k 1.0× 662 1.2× 713 1.5× 35 2.9k
Anna King United Kingdom 37 914 0.6× 621 0.6× 1.1k 1.0× 653 1.1× 489 1.0× 103 3.1k
Andrea Novelli Italy 34 1.3k 0.9× 1.2k 1.1× 744 0.7× 471 0.8× 950 1.9× 166 3.7k
Alfred S. Gin Canada 22 1.6k 1.0× 1.1k 1.0× 1.8k 1.7× 610 1.1× 846 1.7× 37 3.4k
Weiguo Liu United States 30 1.3k 0.9× 960 0.9× 872 0.8× 509 0.9× 1.2k 2.5× 65 3.4k
A. Bryskier France 30 809 0.5× 1.0k 0.9× 730 0.7× 591 1.0× 796 1.6× 121 2.4k
Ayman Noreddin United States 25 1.0k 0.7× 984 0.9× 1.1k 1.1× 473 0.8× 535 1.1× 73 2.9k
N X Chin United States 28 1.4k 0.9× 759 0.7× 979 0.9× 412 0.7× 633 1.3× 62 2.3k

Countries citing papers authored by A. Dalhoff

Since Specialization
Citations

This map shows the geographic impact of A. Dalhoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Dalhoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Dalhoff more than expected).

Fields of papers citing papers by A. Dalhoff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Dalhoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Dalhoff. The network helps show where A. Dalhoff may publish in the future.

Co-authorship network of co-authors of A. Dalhoff

This figure shows the co-authorship network connecting the top 25 collaborators of A. Dalhoff. A scholar is included among the top collaborators of A. Dalhoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Dalhoff. A. Dalhoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Dalhoff, A. & Sabine Schubert. (2009). Pharmacodynamics of moxifloxacin compared with piperacillin/tazobactam, ciprofloxacin, mezlocillin, metronidazole, and ciprofloxacin-metronidazole or -mezlocillin in mono or mixed infections of E.coli, E. Faecalis and B. fragilis in an in vitro pharmacodynamic model.. Infection. 37. 50–51.
3.
Dalhoff, A.. (2008). Comparative Inhibitory and Bactericidal Activities of Finafloxacin (FIN) and Ciprofloxacin (CIP) against Gram-Negative and Gram-Positive UTI-pathogens Under Physiological Conditions and at Varying pH-values. 46th Annual Meeting. 2 indexed citations
4.
Dalhoff, A.. (2005). Immunomodulatory Activities of Fluoroquinolones. Infection. 33(S2). 55–70. 147 indexed citations
5.
Dalhoff, A. & Itamar Shalit. (2003). Immunomodulatory effects of quinolones. The Lancet Infectious Diseases. 3(6). 359–371. 247 indexed citations
6.
Schmidt, André P., Barbara Voith, & A. Dalhoff. (2001). No evidence of active metabolites of faropenem. 41. 23. 1 indexed citations
7.
Dalhoff, A.. (2001). Comparative In Vitro and In Vivo Activity of the C-8 Methoxy Quinolone Moxifloxacin and the C-8 Chlorine Quinolone BAY y 3118. Clinical Infectious Diseases. 32(Supplement_1). S16–S22. 32 indexed citations
8.
Dalhoff, A., Uwe Petersen, & Rainer Endermann. (1996). In vitro Activity of BAY 12-8039, a New 8-Methoxyquinolone. Chemotherapy. 42(6). 410–425. 153 indexed citations
9.
Dalhoff, A.. (1995). Activities of Ciprofloxacin and Sparfloxacin against. Drugs. 49(Supplement 2). 194–196. 8 indexed citations
10.
Bergan, Tom, A. Dalhoff, & R. Rohwedder. (1988). Pharmacokinetics of ciprofloxacin. Infection. 16(S1). S3–S13. 101 indexed citations
11.
Dalhoff, A., et al.. (1986). Penetration of Ciprofloxacin into Gynecological Tissues following Oral and Intravenous Administration. Chemotherapy. 32(1). 7–17. 21 indexed citations
12.
Dalhoff, A., et al.. (1985). Ciprofloxacin Distribution in Prostatic Tissue and Fluid following Oral Administration. Chemotherapy. 31(1). 13–18. 56 indexed citations
13.
Dalhoff, A. & W. Weidner. (1984). Diffusion of ciprofloxacin into prostatic fluid. European Journal of Clinical Microbiology & Infectious Diseases. 3(4). 360–362. 41 indexed citations
14.
15.
Dalhoff, A., et al.. (1982). Pharmacokinetics and Antibacterial Efficacy in vivo of Beta-Lactam Combinations against <i>Proteus vulgaris</i>. Chemotherapy. 28(6). 444–453. 3 indexed citations
16.
17.
Dalhoff, A., et al.. (1981). [Studies on the pharmacokinetics of amoxicillin after intravenous, intramuscular and oral administration (author's transl)].. PubMed. 31(7). 1148–57. 14 indexed citations
18.
Daschner, F., Ulrich Behre, & A. Dalhoff. (1981). Prospective Clinical Trial on the Efficacy of Amoxycillin Administered Twice or Four Times Daily in Children with Respiratory Tract Infections. Journal of International Medical Research. 9(4). 274–276. 7 indexed citations
19.
Dalhoff, A. & H. J. Rehm. (1976). Studies on regulation of tetradecane oxidation inPseudomonas aeruginosa. Applied Microbiology and Biotechnology. 3(3). 193–202. 4 indexed citations
20.
Lode, H., et al.. (1972). [Effects of cephalothin, gentamicin, and their combination on the bacterium Proteus mirabilis].. PubMed. 6(4). 346–53. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. M. Andrews Breakdown of academic impact, for papers by J. M. Andrews Breakdown of academic impact, for papers by H Kropp Breakdown of academic impact, for papers by Anna King Breakdown of academic impact, for papers by Andrea Novelli Breakdown of academic impact, for papers by Alfred S. Gin Breakdown of academic impact, for papers by Weiguo Liu Breakdown of academic impact, for papers by A. Bryskier Breakdown of academic impact, for papers by Ayman Noreddin Breakdown of academic impact, for papers by N X Chin
Rankless by CCL
2026